Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Immunovant, Inc. (IMVT) Institutional Ownership & Insider Trading

226 institutions reported holding Immunovant, Inc. shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 66 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

IMVTImmunovant, Inc.Follow IMVT — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
5.9B
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
9 Nov, in 16 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

226 institutions held 53.5% of the shares. Across filers that reported both quarters, shares held changed -4.8%.

Increased+67New+31Decreased-75Closed-20

Largest moves, shares (millions)

T. Rowe Price Associates+1.5MD. E. Shaw+1.2MMorgan Stanley+0.7MDeep Track Capital-2.2MArmistice Capital-1.8MT. Rowe Price Investment…-1.4M

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters
+3.0Sep 24+2.7Dec 24+14.0Mar 25+1.4Jun 25-0.3Sep 25+13.9Dec 25+1.9Mar 26-5.2Jun 26
QuarterHoldersShares held, MChangeIncreasedNewDecreasedClosed
Jun 26226110-4.8%67317520
Mar 26215111+1.9%85363722
Dec 25194109+15.0%71255022
Sep 2518195-0.3%59304713
Jun 2516796+1.5%67214643
Mar 2519294+17.5%88314225
Dec 2418582+3.5%59255626
Sep 2418179+4.3%67145933

Immunovant, Inc. — questions

Who owns Immunovant, Inc. stock?
226 institutions reported Immunovant, Inc. shares in 13F filings for the quarter ended 2026-06-30. The largest: FMR LLC (7.8%), Deep Track Capital, LP (4.5%), BlackRock, Inc. (3.5%).
Are Immunovant, Inc. insiders buying or selling?
66 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from Immunovant, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.